Compare Regeneron Pharmaceuticals Inc (REGN) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Western Alliance Bancorporation — how do they compare? Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.43B), while Western Alliance Bancorporation trades at $79.37 (market cap $8.72B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 9.6× Western Alliance Bancorporation's market cap, and Western Alliance Bancorporation pays the higher dividend (2.1%). Which is the better fit depends on your goals.
| REGN | WAL | |
|---|---|---|
Market Cap | $83.43B | $8.72B |
Sector | Health | Financials |
52-Week High | $852.03 | $96.08 |
52-Week Low | $555.51 | $66.70 |
Enterprise Value | $78.14B | — |
Dividend Yield | 0.46% | 2.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Western Alliance Bancorporation (WAL) trades at $79.94, down 1.25% on the day, with a bearish technical signal despite strong fundamentals. The bank reported Q2 2026 earnings that met revenue expectations but slightly missed EPS estimates, while maintaining robust profitability with a 25.43% net income margin and 13.43% ROE. Recent developments include the launch of WA VenueX™ digital asset platform and recognition as Arizona's #1 bank by Forbes.
WAL presents a compelling value opportunity with a P/E of 9.02 and strong analyst support (79% buy ratings, $93.86 consensus target), though negative operating cash flow and bearish technical indicators warrant caution. The stock offers 17% upside to consensus target but faces headwinds from declining cash flow and mixed earnings performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
